
~~Claims~~CLAIMS

1. A pharmaceutical composition~~,~~ for use in preventing or treating diabetes or at least one disease selected from metabolic diseases associated therewith, comprising a compound represented by a following chemical Formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates thereof, solvates thereof, or mixtures thereof; and at least one selected from a DPPIV inhibitor, a PPAR agonist, a SGLT2 inhibitor, an insulin secretagogue, a biguanidine drug and an alpha-glucosidase inhibitor:

[Formula 1]








wherein in above Formula 1,

A is an oxadiazole group, a dihydrooxazole group, a thiazole group or a thiadiazole group, in which above A is unsubstituted or substituted with at least one substituent selected from the group consisting of a halogen atom, a C1-C6 straight or branched chain alkyl group, and a C1-C6 straight or branched chain hydroxyalkyl group, in which the alkyl group or the hydroxyalkyl group is each independently unsubstituted or substituted with a halogen atom or a C1-C6 alkoxy group;






B is a pyridine group, a pyrimidine group, a pyrazine group or an oxadiazole group, in which above B is unsubstituted or substituted with at least one substituent selected from the group consisting of a halogen atom, a C1-C6 straight or branched

chain alkyl group, a C1-C6 straight or branched chain hydroxyalkyl group, a C1-C6 alkoxy group and an oxadiazole group, in which the C1-C6 straight or branched chain alkyl group, the C1-C6 straight or branched chain hydroxyalkyl group, the C1-C6 alkoxy group or the oxadiazole group is each independently unsubstituted or substituted with halogen, a C1-C6 alkyl group or a C1-C6 alkoxy group; and

~~X_1 and X_2 are each independently~~X is F, Cl, Br or I.

2. The pharmaceutical composition for use according to claim 1, wherein above A is  ,  ,  ,  or  , and

R_1 to R_3, R_5 and R_6 are each independently at least one substituent selected from the group consisting of a hydrogen atom, a halogen atom, a C1-C6 straight or branched chain alkyl group and a C1-C6 straight or branched chain hydroxyalkyl group, in which the alkyl group or the hydroxyalkyl group is each independently unsubstituted or substituted with a halogen atom or a C1-C6 alkoxy group.

3. The pharmaceutical composition for use according to claim 1, wherein above B is  ,  ,  ,  or  , and

R_7 to R_{11} are each independently substituted with at least one substituent selected from the group consisting of a hydrogen atom, a halogen atom, a C1-C6 straight or branched chain alkyl group, a C1-C6 straight or branched chain hydroxyalkyl group, a C1-C6 alkoxy group and an oxadiazole group, in which the alkyl group, the hydroxyalkyl group, the alkoxy group or the oxadiazole group is each independently unsubstituted or substituted with a halogen atom, a C1-C6 alkyl group or a C1-C6 alkoxy group.

4. The pharmaceutical composition for use according to claim 1, wherein X is F.

5. The pharmaceutical composition for use according to claim 1, wherein above A is an oxadiazole group substituted with a C1-C6 straight or branched chain alkyl group, above B is a pyrimidine group substituted with a C1-C6 straight or branched chain alkyl group, and X is F.

6. The pharmaceutical composition for use according to claim 1, wherein the compound represented by above Formula 1 is 3-(4-(3-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)propoxy)-2,6-difluorophenyl)-5-isopropyl-1,2,4-oxadiazole.

7. The pharmaceutical composition for use according to claim 6, wherein the pharmaceutical composition comprises at least one of the DPPIV inhibitor, the PPAR agonist, the SGLT2 inhibitor, the insulin secretagogue, the biguanidine drug and the alpha-glucosidase inhibitor.

8. The pharmaceutical composition for use according to claim 6, wherein the pharmaceutical composition comprises at least one of evogliptin, sitagliptin, elafibranor, dapagliflozin, glimepiride, metformin and voglibose.

9. The pharmaceutical composition ~~of claim~~for use according to claim 1, wherein the pharmaceutical composition comprises at least one of the DPPIV inhibitor, the PPAR agonist, the SGLT2 inhibitor, the insulin secretagogue, the biguanidine drug and the alpha-glucosidase inhibitor.

10. The pharmaceutical composition for use according to claim 9, wherein the pharmaceutical composition comprises at least one of evogliptin, sitagliptin, elafibranor, dapagliflozin, glimepiride, metformin and voglibose.

11. The pharmaceutical composition for use according to claim 1, wherein the metabolic disease is at least one of obesity and dyslipidemia.

12. ~~Use of a pharmaceutical composition, comprising the compound represented by Formula 1 according to claim 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates thereof, solvates thereof, or mixtures thereof; and at least one selected from a DPPIV inhibitor, a PPAR agonist, a SGLT2 inhibitor, an insulin secretagogue, a biguanidine drug and an alpha-glucosidase inhibitor, for preventing or treating diabetes or at least one disease selected from metabolic diseases associated therewith.~~

~~13.~~ Use of a pharmaceutical composition, comprising a compound represented by Formula 1 according to claim 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates thereof, solvates thereof, or mixtures thereof; and at least one selected from a DPPIV inhibitor, a PPAR agonist, a SGLT2 inhibitor, an insulin secretagogue, a biguanidine drug and an alpha-glucosidase inhibitor, in the manufacture of a ~~pharmaceutical preparation~~medicament for preventing or treating diabetes or at least one disease selected from metabolic diseases associated therewith.

~~14. A method for preventing or treating diabetes or at least one disease selected from metabolic diseases associated therewith comprising administering a therapeutically effective amount of a pharmaceutical composition including a compound represented by Formula 1 according to claim 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates thereof, solvates thereof, or mixtures thereof; and at least one selected from a DPPIV inhibitor, a PPAR agonist, a SGLT2 inhibitor, an insulin secretagogue, a biguanidine drug and an alpha-glucosidase inhibitor, into a subject in need of treatment.~~